Price T Rowe Associates Inc Biocryst Pharmaceuticals Inc Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,252,749 shares of BCRX stock, worth $17.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,252,749

Previous 1,948,984 15.59%

Holding current value

$17.1 Million

Previous $12 Million 42.14%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$6.41 - $8.69 $1.95 Million - $2.64 Million	303,765 Added 15.59%	2,252,749 $17.1 Million
Q2 2024 Aug 14, 2024	BUY	$4.13 - $6.79 $7.51 Million - $12.3 Million	1,818,209 Added 1390.33%	1,948,984 $12 Million
Q1 2024 May 15, 2024	BUY	$4.89 - $7.65 $83,574 - $130,746	17,091 Added 15.03%	130,775 $665,000
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $46,657 - $63,428	9,369 Added 8.98%	113,684 $681,000
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $56,853 - $67,106	8,473 Added 8.84%	104,315 $739,000
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $59,257 - $75,008	8,514 Added 9.75%	95,842 $675,000
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $27,821 - $41,487	3,504 Added 4.18%	87,328 $729,000
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $22,102 - $29,891	2,105 Added 2.58%	83,824 $962,000
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $60,132 - $82,536	5,573 Added 7.32%	81,719 $1.03 Million
Q2 2022 Aug 15, 2022	SELL	$7.89 - $17.88 $38,369 - $86,950	-4,863 Reduced 6.0%	76,146 $806,000
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $79,024 - $135,079	-6,836 Reduced 7.78%	81,009 $1.32 Million
Q4 2021 Feb 14, 2022	SELL	$11.18 - $15.46 $67,214 - $92,945	-6,012 Reduced 6.41%	87,845 $1.22 Million
Q3 2021 Nov 15, 2021	BUY	$14.21 - $17.65 $24,029 - $29,846	1,691 Added 1.83%	93,857 $1.35 Million
Q2 2021 Aug 16, 2021	SELL	$9.5 - $17.24 $36,328 - $65,925	-3,824 Reduced 3.98%	92,166 $1.46 Million
Q1 2021 May 17, 2021	BUY	$7.37 - $13.61 $63,713 - $117,658	8,645 Added 9.9%	95,990 $976,000
Q4 2020 Feb 16, 2021	BUY	$3.37 - $8.61 $294,352 - $752,040	87,345 New	87,345 $651,000

Others Institutions Holding BCRX

# of Institutions

278

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Biocryst Pharmaceuticals Inc Transaction History